X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7) 7
middle aged (6) 6
chemotherapy (5) 5
female (5) 5
index medicus (5) 5
oncology (5) 5
adult (4) 4
aged (4) 4
cancer (4) 4
male (4) 4
treatment outcome (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
drug administration schedule (3) 3
hematology, oncology and palliative medicine (3) 3
antineoplastic agents - therapeutic use (2) 2
breast cancer (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - mortality (2) 2
cancer therapies (2) 2
care and treatment (2) 2
chemotherapy, adjuvant (2) 2
clinical trials (2) 2
cytarabine (2) 2
cytarabine - adverse effects (2) 2
cytarabine - therapeutic use (2) 2
disease-free survival (2) 2
dosage and administration (2) 2
drug therapy (2) 2
follow-up studies (2) 2
gastric cancer (2) 2
gene expression (2) 2
hematology (2) 2
immunohistochemistry (2) 2
kaplan-meier estimate (2) 2
lymphomas (2) 2
medical research (2) 2
neoplasm proteins - genetics (2) 2
patient outcomes (2) 2
patients (2) 2
prognosis (2) 2
surgery (2) 2
survival (2) 2
survival analysis (2) 2
therapy (2) 2
usage (2) 2
1st-line treatment (1) 1
5-fluorouracil (1) 1
aberrations (1) 1
abridged index medicus (1) 1
actins - analysis (1) 1
adaptor proteins, signal transducing - genetics (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - surgery (1) 1
adjuvant (1) 1
adjuvant chemotherapy (1) 1
adjuvant therapy (1) 1
adjuvant treatment (1) 1
adjuvants, pharmaceutic - therapeutic use (1) 1
administration, oral (1) 1
adolescent (1) 1
age factors (1) 1
aged patients (1) 1
antimetabolites, antineoplastic - adverse effects (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents, hormonal - adverse effects (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antitank weapons (1) 1
arimidex (1) 1
b-cell cll-lymphoma 10 protein (1) 1
b-cell lymphoma (1) 1
bendamustine (1) 1
bendamustine hydrochloride - administration & dosage (1) 1
bendamustine hydrochloride - adverse effects (1) 1
bendamustine hydrochloride - therapeutic use (1) 1
biological effects (1) 1
biomarkers, tumor - genetics (1) 1
breast (1) 1
breast neoplasms - diagnosis (1) 1
breast neoplasms - pathology (1) 1
breast neoplasms - surgery (1) 1
burkitts-lymphoma (1) 1
camptothecin - adverse effects (1) 1
camptothecin - analogs & derivatives (1) 1
camptothecin - therapeutic use (1) 1
carcinoma, ductal, breast - diagnosis (1) 1
carcinoma, ductal, breast - drug therapy (1) 1
carcinoma, ductal, breast - mortality (1) 1
carcinoma, ductal, breast - surgery (1) 1
carcinomas (1) 1
caspases - genetics (1) 1
central nervous system diseases (1) 1
central nervous system neoplasms - drug therapy (1) 1
central nervous system neoplasms - mortality (1) 1
central nervous system neoplasms - radiotherapy (1) 1
central-nervous-system (1) 1
cerebrospinal-fluid (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Journal Article
Human Pathology, ISSN 0046-8177, 2009, Volume 40, Issue 5, pp. 645 - 652
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, p. e0136731
Journal Article
世界胃肠外科杂志:英文版(电子版), ISSN 1948-9366, 2014, Volume 6, Issue 4, pp. 55 - 58
Gastric cancer is the second leading cause of death from malignant disease worldwide.Although complete surgical resection remains the only curative modality... 
Lymphadenectomy | treatment | Chemotherapy | Targeted | Multimodal | therapy | Neoadjuvant | Gastric | cancer | Adjuvant | Gastrectomy | Radiotherapy | Multimodal treatment | Neoadjuvant therapy | Targeted therapy | Minireviews | Gastric cancer | Adjuvant therapy
Journal Article
Oncology, ISSN 0030-2414, 10/2007, Volume 71, Issue 5-6, pp. 341 - 346
Objective: Combination therapies of fluorouracil (FU) with irinotecan (CPT-11) and docetaxel plus cisplatin have been proven to be active in metastatic gastric... 
Clinical Study
Journal Article
Oncology, ISSN 0030-2414, 10/2007, Volume 71, Issue 5-6, pp. 341 - 346
Objective: Combination therapies of fluorouracil ( FU) with irinotecan ( CPT- 11) and docetaxel plus cisplatin have been proven to be active in metastatic... 
Irinotecan | Adjuvant chemotherapy | Gastric cancer | Docetaxel | adjuvant chemotherapy | PLUS CISPLATIN | irinotecan | METAANALYSIS | gastric cancer | CURATIVE RESECTION | FOLINIC ACID | FLUOROURACIL | COMBINATION | CANCER | 5-FLUOROURACIL | ONCOLOGY | docetaxel | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Cisplatin - administration & dosage | Feasibility Studies | Fluorouracil - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Chemotherapy, Adjuvant - adverse effects | Adult | Female | Leucovorin - therapeutic use | Neutropenia - chemically induced | Taxoids - adverse effects | Camptothecin - analogs & derivatives | Mitomycin - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Drug Administration Schedule | Survival Rate | Treatment Outcome | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Digestive System Surgical Procedures | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Adolescent | Cisplatin - adverse effects | Aged | Stomach Neoplasms - surgery | Mitomycin - administration & dosage | Adenocarcinoma - surgery | Medical research | Oncology | Chemotherapy | Gastrointestinal diseases | Surgery | Cancer
Journal Article
Oncology, ISSN 0030-2414, 10/2007, Volume 71, Issue 5-6, pp. 471 - 473
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.